Suneel Gupta - 25 Nov 2024 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role
Chief Development Officer
Signature
/s/ Matthew Gosling, Attorney-in-Fact for Suneel Gupta
Issuer symbol
PTGX
Transactions as of
25 Nov 2024
Transactions value $
-$3,908,853
Form type
4
Filing time
27 Nov 2024, 19:09:12 UTC
Previous filing
28 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTGX Common Stock Options Exercise $332K +45K +24.38% $7.38 230K 25 Nov 2024 Direct F1
transaction PTGX Common Stock Options Exercise $361K +45K +19.6% $8.02 275K 25 Nov 2024 Direct
transaction PTGX Common Stock Options Exercise $663K +85K +30.95% $7.80 360K 25 Nov 2024 Direct
transaction PTGX Common Stock Sale -$4.76M -103K -28.76% $46.04 256K 25 Nov 2024 Direct F2, F3
transaction PTGX Common Stock Options Exercise $365K +30K +11.71% $12.17 286K 26 Nov 2024 Direct
transaction PTGX Common Stock Sale -$873K -19.2K -6.71% $45.50 267K 26 Nov 2024 Direct F2, F4
transaction PTGX Common Stock Options Exercise $5.48K +450 +0.17% $12.17 267K 26 Nov 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTGX Stock Option (right to buy) Options Exercise $0 -45K -100% $0.00 0 25 Nov 2024 Common Stock 45K $7.38 Direct F5
transaction PTGX Stock Option (right to buy) Options Exercise $0 -45K -100% $0.00 0 25 Nov 2024 Common Stock 45K $8.02 Direct F5
transaction PTGX Stock Option (right to buy) Options Exercise $0 -85K -100% $0.00 0 25 Nov 2024 Common Stock 85K $7.80 Direct F5
transaction PTGX Stock Option (right to buy) Options Exercise $0 -30K -24.24% $0.00 93.8K 26 Nov 2024 Common Stock 30K $12.17 Direct F6
transaction PTGX Stock Option (right to buy) Options Exercise $0 -450 -0.48% $0.00 93.3K 26 Nov 2024 Common Stock 450 $12.17 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes an aggregate of 1,326 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2024.
F2 Sale to cover the exercise price of the options.
F3 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.63 to $46.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.23 to $45.81. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5 These stock options are fully vested.
F6 The stock option vests in 48 equal monthly installments following the date of grant.